US Oncology

The Genomic Cancer Care Alliance — which currently involves founding organizations Fox Chase Cancer Center, Scripps Genomic Medicine, Omicia, El Camino Hospital, and the Translational Genomics Research Institute — plans to launch a pilot study to investigate the ability of whole-genome sequencing to guide treatment for patients who have responded poorly to initial therapy.

The alliance is primarily funded by Life Technologies for now and will use the company's SOLiD 4 sequencing platform. Other founding partners include the Fox Chase Cancer Center, Scripps Genomic Medicine, and the Translational Genomics Research Institute.

The firm has teamed with Fox Chase Cancer Center, Scripps Genomic Medicine, and the Translational Genomics Research Institute to help people with cancer gain access to better treatment options through analysis of their genomic information.

The goal of the study is "to demonstrate whether genomic sequencing of cancer tissues can provide clues for treatment strategies for these individuals," according to the partners.

Life Technologies, the Translational Genomics Research Institute, and US Oncology plan to sequence tumor-normal genomes for 14 breast cancer patients to determine whether this sequencing can be used to better tailor treatments.

The joint venture in the Dallas area will offer clinical lab services, molecular diagnostics, and pharmacogenomic tests and will focus on cancer.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.